Sentences with phrase «of ovarian cancer research»

«By combining my laboratory's expertise in ovarian cancer biology and Dr. Xu's expertise in bioinformatics, we were able to uncover a potentially novel drug approach to treat ovarian cancer,» said co-senior author Analisa DiFeo, PhD, the Norma C. and Albert I. Geller Designated Professor of Ovarian Cancer Research and assistant professor in the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine.

Kelly and accomplished master baker and cake decorator Buddy Valastro, from TLC's «Cake Boss,» recently joined forces at a fun event to bake lavishly decorated cakes in support of The Ovarian Cancer Research...

Not exact matches

Electrolux and Kelly Ripa are proud to support the Ovarian Cancer Research Fund whose mission is to fund research to find a method of early detection and ultimately a cure for OvarianResearch Fund whose mission is to fund research to find a method of early detection and ultimately a cure for Ovarianresearch to find a method of early detection and ultimately a cure for Ovarian Cancer.

Research indicates that breastfeeding is beneficial for both you and your baby — you experience lower risk of ovarian cancer, postpartum depression, breast cancer and diabetes, while your baby receives all the good nutrients and also has a lower risk of diseases like diabetes, obesity, asthma and lower respiratory infections.

Reams of research have linked breastfeeding to scores of benefits for both mom and baby: breast - fed babies aren't as likely to fall prey to obesity, ear infections or diabetes; breast - feeding moms benefit from a decreased risk of breast and ovarian cancer.

Recent research demonstrates that lactating women have an earlier return to prepregnant weight, 41 delayed resumption of ovulation with increased child spacing,42 - 44 improved bone remineralization postpartum45 with reduction in hip fractures in the postmenopausal period, 46 and reduced risk of ovarian cancer47 and premenopausal breast cancer.48

Research shows that women who have breastfed have lower chances of getting ovarian cancer and breast cancer later in life.

Her work in protein research at Hunter and her grandmother's recent diagnosis of ovarian cancer sparked an interest in cancer biology and immunology, but Rezende is eager to sample other fields.

The research shows that ONA reduces the progression of malignant ovarian cancer tumors by interfering with the pro-tumor function of myeloid cells.

This discovery is a result of research on the effects of ONA on a preclinical model of epithelial ovarian cancer (EOC) both in vivo and in vitro.

Funding for the study was provided by the National Institutes of Health (P50 CA083638, R21 CA156224, 5P30 CA016520 - 36), the Marcus Foundation, the Ovarian Cancer Immunotherapy Initiative, the Ludwig Institute for Cancer Research at the University of Lausanne, and the Ovacure Foundation.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

«What we've discovered will help clinicians to better treat women with ovarian cancer,» says Dr. Ben Tsang, senior scientist at the Ottawa Hospital Research Institute and professor at the University of Ottawa.

«However, additional research is needed to further evaluate the therapy for this type of ovarian cancer.»

Cancer researcher Janet Sawicki of the Lankenau Institute for Medical Research in Pennsylvania, chemical engineer Robert Langer of MIT, and their colleagues are investigating biodegradable nanoparticles to deliver gene therapy for ovarian cCancer researcher Janet Sawicki of the Lankenau Institute for Medical Research in Pennsylvania, chemical engineer Robert Langer of MIT, and their colleagues are investigating biodegradable nanoparticles to deliver gene therapy for ovarian cancercancer.

Researchers using data collected by the Ovarian Cancer Association Consortium have discovered uncommon variants in new regions of the genome that influence ovarian cancer risk, and will present their findings on April 6, 2014 at the American Association for Cancer Research Annual Meeting in San DieOvarian Cancer Association Consortium have discovered uncommon variants in new regions of the genome that influence ovarian cancer risk, and will present their findings on April 6, 2014 at the American Association for Cancer Research Annual Meeting in San DiegCancer Association Consortium have discovered uncommon variants in new regions of the genome that influence ovarian cancer risk, and will present their findings on April 6, 2014 at the American Association for Cancer Research Annual Meeting in San Dieovarian cancer risk, and will present their findings on April 6, 2014 at the American Association for Cancer Research Annual Meeting in San Diegcancer risk, and will present their findings on April 6, 2014 at the American Association for Cancer Research Annual Meeting in San DiegCancer Research Annual Meeting in San Diego, CA.

Acknowledging that «this is not a big study, in terms of the overall number of cases, for ovarian cancer it's a very big study,» explains Annekatrin Lukanova of the International Agency for Cancer Research in Lyon, Fcancer it's a very big study,» explains Annekatrin Lukanova of the International Agency for Cancer Research in Lyon, FCancer Research in Lyon, France.

A Mayo Clinic research team has found evidence suggesting that the controversial practice of ovary removal in premenopausal women to prevent ovarian cancer should be discontinued in women who are not at high risk of cancer.

The lab of co-author Dr. Robert Bast Jr., an expert in ovarian cancer and vice president for translational research at MD Anderson, inserted gel - bound carbon nanotubes into the ovaries of rodents to mimic the accumulations that are expected for nanotubes linked to special antibodies that recognize tumor cells.

The research team with international collaborators analysed more than 100 patient samples from ovarian and other cancer types to discover a distinct population of cells found in some tumours.

Women of reproductive age who have thyroid cancer should be cautious about receiving radioactive iodine treatment, which affects their remaining egg supply — their ovarian reserve — and may affect their fertility, new research from Israel finds.

Now a team led by Lin Zhang, PhD, research associate professor in the Department of Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, has mined those sequences to identify a non-protein-coding RNA whose expression is linked to ovarian cancer.

«Dr. Moore's research is ground - breaking in the area of ovarian cancer, and it's all happening in his laboratory in the Knowledge District of Providence.»

Nearly 20 percent of women with ovarian cancer do not undergo surgery, despite it being a standard part of treatment recommendations, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

Dr. Narod, who is also a Tier 1 Canada Research Chair in Breast Cancer, recommends that doctors should consider adopting a standard model of care for all women diagnosed with advanced - stage ovarian cCancer, recommends that doctors should consider adopting a standard model of care for all women diagnosed with advanced - stage ovarian cancercancer:

Dr James Brenton, Cancer Research UK's ovarian cancer expert, says: «A blood test to find women at risk of ovarian cancer is an exciting prospect, but this work still needs to be tested in women to see if it can save Cancer Research UK's ovarian cancer expert, says: «A blood test to find women at risk of ovarian cancer is an exciting prospect, but this work still needs to be tested in women to see if it can save cancer expert, says: «A blood test to find women at risk of ovarian cancer is an exciting prospect, but this work still needs to be tested in women to see if it can save cancer is an exciting prospect, but this work still needs to be tested in women to see if it can save lives.

New research from George Vasmatzis, Ph.D., of the Department of Laboratory Medicine and Pathology at Mayo Clinic, finds liquid biopsies from blood tests and DNA sequencing can detect a return of ovarian cancer long before a tumor reappears.

Up to half of women with advanced - stage ovarian cancer might be cured, compared to the current 20 per cent survival rate, argues Dr. Steven Narod, senior scientist at Women's College Research Institute, who calls for a new standard of treatment for women with late - stage ovarian cancer.

«There is currently no national screening programme for ovarian cancer, as research to date has been unable to provide enough evidence that any one method would improve early detection of tumours.

Dr. Vasmatzis» research on the «Quantification of Somatic Chromosomal Rearrangements in Circulating Cell - free DNA From Ovarian Cancers» is published in the July 20 edition of Scientific Reports.

The results come from analysis of one arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), the world's largest ovarian cancer screening trial, led by UCL and funded by the Medical Research Council, Cancer Research UK, Department of Health and The Eve Ovarian Cancer Screening (UKCTOCS), the world's largest ovarian cancer screening trial, led by UCL and funded by the Medical Research Council, Cancer Research UK, Department of Health and The Eve ACancer Screening (UKCTOCS), the world's largest ovarian cancer screening trial, led by UCL and funded by the Medical Research Council, Cancer Research UK, Department of Health and The Eve ovarian cancer screening trial, led by UCL and funded by the Medical Research Council, Cancer Research UK, Department of Health and The Eve Acancer screening trial, led by UCL and funded by the Medical Research Council, Cancer Research UK, Department of Health and The Eve ACancer Research UK, Department of Health and The Eve Appeal.

Research like this gives scientists and doctors a clearer view of what is driving this form of ovarian cancer and has the potential to lead to new treatments.

«For decades, women have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced - stage ovarian cancer, but there are many survivors as well,» said Dr. Narod, senior scientist at Women's College Research Institute.

In lab experiments, the research team used cell lines derived from 40 patient tumour samples to identify that CD151 contributes to the survival of cells of high - grade serous ovarian cancer origin.

The research was the first to comprehensively examine the six major flavonoid subclasses present in the normal diet with ovarian cancer risk, and the first to investigate the impact of polymers and anthocyanins.

«What we did in this paper is engineer our sensor to be about 15 times better than a previous version, and then compared it against a blood biomarker in a mouse model of ovarian cancer to show that we could beat it,» says Sangeeta Bhatia, the John and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science, a member of MIT's Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science, and the senior author of the cancer to show that we could beat it,» says Sangeeta Bhatia, the John and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science, a member of MIT's Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science, and the senior author of the Cancer Research and Institute for Medical Engineering and Science, and the senior author of the study.

The research reveals that women who consume foods containing flavonols and flavanones (both subclasses of dietary flavonoids) significantly decrease their risk of developing epithelial ovarian cancer, the fifth - leading cause of cancer death among women.

«Scientists track ovarian cancers to site of origin: Fallopian tubes: Small study offers proof of concept, support for wider research.»

The collaborative research team — which included experts in gynecological cancer, genomics, pathology and computational biology — performed a comprehensive genetic analysis of ovarian and endometrial CSs.

In earlier research, Barbolina discovered that a fractalkine receptor — a protein found on the cell surface — is expressed in the majority of ovarian cancer cases.

Blocking a protein found on the surface of ovarian cancer cells could prevent or reduce the spread of the disease to other organs, according to new research at the University of Illinois at Chicago.

Although this research was conducted on ovarian cancer cells, the ground - breaking results are applicable to a wider range of cancers.

Longer term, they want to quickly diagnose additional cancer types, including ovarian and pancreatic cancers, which are fast - spreading and require early detection for a patient to survive, says Goda, who was recently appointed as a chemistry professor at the University of Tokyo but will continue his research with U.C.L.A..

While previous research had shown some effectiveness of this molecule in a mouse model of ovarian cancer, that benefit was limited by the immunosuppressive environment within tumors, particularly the presence of regulatory T cells (Tregs).

Many of these genes are usually switched off in adults, but previous research has shown that in many cancers — including prostate, ovarian, and brain cancer, melanoma, and leukemia — HOX genes are switched back on, helping the cancer cells to proliferate and survive.

Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that ovarian tumors harbor highly reactive killer T cells — which kill infected and cancerous cells — and demonstrates how they can be identified and selectively grown for use in personalized, cell - based immunotherapies.

Now, however, a team led by Merajver and another headed by Ellen Solomon and John Trowsdale of the Imperial Cancer Research Fund in London say that they have both found damaged copies of BRCA1 in ovarian tumours from women with no family history of cancer (Nature Genetics, vol 9, p 343 andCancer Research Fund in London say that they have both found damaged copies of BRCA1 in ovarian tumours from women with no family history of cancer (Nature Genetics, vol 9, p 343 andcancer (Nature Genetics, vol 9, p 343 and 439).

Women with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medcancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of MedCancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medicine.

Professor Paul Pharoah, professor of cancer epidemiology at the Cancer Research UK Cambridge Institute, said: «Our work has found a valuable piece of the puzzle behind ovarian cancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatestcancer epidemiology at the Cancer Research UK Cambridge Institute, said: «Our work has found a valuable piece of the puzzle behind ovarian cancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatestCancer Research UK Cambridge Institute, said: «Our work has found a valuable piece of the puzzle behind ovarian cancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatestcancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatest risk.

I was honored to receive the Mentor Award from the American Congress of Obstetricians and Gynecologists in 2012 and the Foundation for Women's Cancer's Excellence in Ovarian Cancer Research Prize in 2013.